Abstract: Hybrid GNNs, which learn both long-term structural information encoded in static graphs and temporal interactions within dynamic graphs, have attracted attention for their high predictive ...

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized ...

In patients with oligometastatic prostate cancer, metastasis-directed therapy plus standard of care was associated with significant improvements in progression-free survival (PFS), radiographic PFS, ...

“Modern system-on-chips (SoCs) are becoming prone to numerous security vulnerabilities due to their ever-growing complexity and size. Therefore, a comprehensive security verification framework is ...

Tucatinib was associated with an 36% reduction in the risk of disease progression or death. Adding the TKI inhibitor tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab ...

DUBLIN, Jan. 6, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab ...

Perplexity’s live retrieval makes its citations look more like Google’s search results. ChatGPT and Gemini rely more on selective, model-driven choices than on current rankings. Google visibility ...

MONDAY, Oct. 27, 2025 (HealthDay News) -- For young patients with primary multimetastatic Ewing sarcoma, pazopanib is well-tolerated and effective, according to a study published online Oct. 22 in ...

BeyondSpring presents Phase 2 data showing Plinabulin's potential in metastatic NSCLC after PD-1/L1 therapy, with promising survival rates. BeyondSpring Inc. announced promising interim results from ...

DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial ...